Huasun(SZ:000790) Xin Lang Zheng Quan·2025-10-30 14:07Core Viewpoint - Huasheng Technology, a well-known pharmaceutical company in China, focuses on the research and development of traditional Chinese medicine and biopharmaceuticals, but its financial performance lags behind industry leaders [1][2]. Financial Performance - In Q3 2025, Huasheng Technology reported revenue of 457 million yuan, ranking 57th among 69 companies in the industry, significantly lower than the top performer, Baiyunshan, with 61.606 billion yuan, and Yunnan Baiyao at 30.654 billion yuan [2]. - The company's net profit for the same period was -97.1142 million yuan, placing it 64th in the industry, while Yunnan Baiyao and Baiyunshan reported net profits of 4.789 billion yuan and 3.398 billion yuan, respectively [2]. Financial Ratios - As of Q3 2025, Huasheng Technology's debt-to-asset ratio was 48.98%, slightly higher than the previous year's 48.94% and above the industry average of 32.81% [3]. - The gross profit margin for the same period was 45.48%, down from 47.92% year-on-year and below the industry average of 52.44% [3]. Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 5.50% to 37,000, while the average number of circulating A-shares held per account increased by 5.82% to 16,800 [5]. - Among the top ten circulating shareholders, Huatai-PB Zhongzheng Chinese Medicine ETF ranked eighth with 3.886 million shares, an increase of 1.0127 million shares from the previous period [5]. Executive Compensation - The chairman of Huasheng Technology, Huang Mingliang, received a salary of 799,700 yuan in 2024, an increase of 210,800 yuan compared to 588,900 yuan in 2023 [4].